
Cytokinetics adds Phase 3 data to MYQORZO label
Key points
- Cytokinetics (NASDAQ:CYTK) received FDA approval to add Phase 3 MAPLE-HCM trial results comparing MYQORZO with metoprolol to its U.S. prescribing information.
- MYQORZO met the primary exercise-capacity endpoint and significantly improved five of six secondary endpoints, with similar overall adverse-event rates between treatment groups.
- The update adds comparative clinical evidence but does not expand MYQORZO's existing approved indication for symptomatic obstructive hypertrophic cardiomyopathy.
Cytokinetics (NASDAQ:CYTK) received FDA approval to update MYQORZO's prescribing information with Phase 3 MAPLE-HCM results comparing the treatment with metoprolol in adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
The regulatory update follows a clinical trial evaluating MYQORZO as a single therapy against metoprolol, a beta-blocker commonly used to manage heart conditions, in patients with obstructive HCM.
MAPLE-HCM enrolled 175 patients in a randomized, double-blind, active-comparator study, with the primary endpoint measuring changes in peak oxygen uptake from baseline to Week 24 to assess exercise capacity.
MYQORZO met the primary endpoint and significantly improved five of six secondary endpoints, while overall adverse-event rates were similar between treatment groups, although hypertension occurred in 15% of MYQORZO patients compared with 3% receiving metoprolol.
MYQORZO remains approved for adults with symptomatic oHCM to improve functional capacity and symptoms, with its existing boxed warning for heart failure due to systolic dysfunction and required heart-function monitoring.
Cytokinetics is also developing aficamten for non-obstructive hypertrophic cardiomyopathy, with the company expecting to submit a separate supplemental FDA application based on its Phase 3 ACACIA-HCM results in the fourth quarter of 2026.

